**EXHIBIT      10.1**

*****      Confidential treatment has been requested for portions of this exhibit. The      copy      filed herewith omits the information subject to the confidentiality treatment      request, and such omissions are designated as [***]. A complete version of      this      exhibit has been filed separately with the Securities and Exchange Commission      pursuant to the request for confidential treatment.**

**AMENDMENT**

| 1.   | IND.                Merck shall transfer, or cause to be transferred, to DOV the current                open                IND for DOV 21,947 to enable DOV to conduct Clinical Trials including                those contemplated by this Amendment. Upon the transfer of the IND                to DOV,                DOV shall be solely responsible for performance of all Clinical Trials                pursuant to the IND and compliance with the conditions of the IND.                The                exclusive license granted to Merck pursuant to Section 3.1 of the                Agreement shall have any and all exceptions (the “License Exceptions”)                sufficient to permit DOV, and one or more third parties engaged by                DOV on                its behalf, to conduct and perform any and all research and development,                Clinical Trials including those required by Paragraphs 3, 4 and 5                below                and any other activities necessary or appropriate to fulfill DOV’s rights                and obligations under this Amendment. Additionally, Merck hereby                grants to                DOV (a) a non-exclusive license under Merck Patent Rights (if any)                and                Merck Know-How (if any) and (b) the right to permit, under Merck                Patent                Rights (if any) and Merck Know-How (if any), one or more third parties                engaged by DOV to make or use, on DOV’s behalf, DOV 21,947 and any Product                containing DOV 21,947 and methods, in the case of either of the foregoing                clauses (a) or (b), sufficient to permit DOV to conduct and perform                any                and all research and development, Clinical Trials including those                required                by Paragraphs 3, 4 and 5 below and any other activities necessary                or                appropriate to fulfill DOV’s rights and obligations under this Amendment. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | Drug                Supply.                Merck shall supply to DOV at Merck’s expense all Merck’s supply existing                as of the Amendment Effective Date of DOV 21,947 that is qualified                as of                the Amendment Effective Date for use in                humans. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.   | Phase                Ib and R&D.                DOV shall conduct at its expense a Phase Ib Clinical Trial with respect                to                DOV 21,947 (the “Phase Ib”) on normal volunteers in order to form a basis                for a Phase II Clinical Trial with respect to DOV 21,947, as more                fully                described below (the “First Phase II”). DOV shall have the right, during                the Phase Ib, First Phase II and Second Phase II (as defined below),                and                upon consultation with Merck, to conduct at DOV’s expense further                development activities on DOV 21,947 including formulation, longer                term                toxicology, ADME and other pre-clinical development and Clinical                Trials                (collectively, “Further R&D”). |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | First                Phase II.                DOV shall conduct at its expense the First Phase II, which shall                be a                dose-response, placebo controlled study. The results of the First                Phase II                shall be taken into account in designing a successive Phase II Clinical                Trial, as more fully described below (the “Second Phase II”). |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | Second                Phase II.                DOV shall conduct at its expense the Second Phase II, which shall                have as                its objective determining the superiority of DOV 21,947 over an SSRI                in                the treatment of outpatients with major depressive disorder. No later                than                the commencement of the Second Phase II, the parties shall agree                in                writing on the design of the Second Phase II and what constitutes                successful completion of the Second Phase II (“Successful”). Whether such                study is Successful shall be determined without reference to Section                1.74                of the Agreement. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.   | DOV                Development Plan and Budget.                Within ninety (90) days following the Amendment Effective Date DOV                shall                present to Merck the development plan and budget for the Phase Ib                and                First Phase II (the “DOV Plan”). The DOV Plan shall include spending caps                for the DOV personnel involved in carrying out the DOV Plan for up                to                $[***] for the Phase Ib and $[***] for the Second Phase II. DOV shall                update the DOV Plan based on new information developed for Further                R&D                and Second Phase II. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.   | Reimbursement                of DOV.                If the Second Phase II is Successful or if Merck otherwise elects                as                contemplated by this Paragraph 7 or Paragraphs 8 or 11 below, Merck                shall                reimburse DOV as follows (the “Reimbursement Payment): [***]% of DOV’s                actual costs for the Phase Ib and Second Phase II and [***]% of its                actual                costs for the First Phase II and Further R&D, in each case upon                presentation of an itemization of such costs calculated to include                out of                pocket and internal professional time at CRO rates to be agreed upon                by                the parties; provided that Merck shall not be required to reimburse                DOV                for Further R&D expenses that were not approved by Merck prior to                being incurred. If the Second Phase II is not Successful, Merck may                elect                but is not required to make the Reimbursement Payment. The Reimbursement                Payment shall be due (a) forty-five (45) days following the later                of (i)                the date that DOV provides Merck with all Information and Inventions                generated as a result of Phase Ib, First Phase II, Second Phase II                and                Further R&D, and (ii) the date on which DOV delivers to Merck data                demonstrating that the Second Phase II is Successful, (b) in the                event                that the Second Phase II is not Successful and Merck nevertheless                elects                to make the Reimbursement Payment, no later than sixty (60) days                after the                delivery to Merck of data demonstrating that the Second Phase II                was not                Successful or (c) in the event that DOV terminates this Amendment                in                accordance with Paragraph 11 below after the commencement of the                Second                Phase II, and if Merck exercises its rights under Paragraph 11, not                later                than the date specified in Paragraph                11. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8.   | Merck                Payment and Continuing Obligations.                (a) If the Second Phase II is Successful or if Merck otherwise elects                to                make the Reimbursement Payment, it shall re-assume all development                and                other obligations under the Agreement with respect to DOV                21,947. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.   | Pivotal                Trial Milestone.                If the Second Phase II is Successful, Merck shall, notwithstanding                anything to the contrary in the Agreement (including without limitation                Section 5.3(c) of the Agreement), make the development milestone                payment                called for by Section 5.3(a)(i) of the Agreement. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.   | Additional                Licenses to Merck.                Within thirty (30) days of the Amendment Effective Date, DOV shall                transfer all Information and Inventions relating to the Additional                Compounds (defined below) (the “Transfer Date”). DOV hereby grants to                Merck, free of charge, for a period commencing on the date of this                Amendment and ending 12 months following the Transfer Date, an exclusive                license in the Territory under the DOV Patent Rights, DOV’s and its                Controlled Affiliates’ rights in the Joint Patent Rights, and DOV                Know-How, but with no right to sublicense, to conduct pre-clinical                testing                on three additional triple reuptake inhibitor compounds of DOV, namely,                [***] (“Additional Compounds”), whereupon Merck shall be entitled to                select (in writing no later than 30 days after the end of such 12-month                period) with no up-front payment to DOV one of such Additional Compounds                for inclusion in the Agreement as a Compound and all references in                the                Agreement to DOV 21,947 shall be deemed to mean DOV 21,947 and/or                the                Additional Compound that has been selected by Merck. Upon such selection,                all know-how, data and related inventions and/or intellectual property                related to such other two Additional Compounds created or developed                by or                on behalf of Merck during such 12 month period (the “Rejected Compound                IP”) shall be returned or transferred to and be owned by DOV. In                furtherance thereof, Merck hereby assigns and transfers, and shall                assign                and transfer, to DOV all ownership and interest in the Rejected Compound                IP and any and all intellectual property rights in and to any Rejected                Compound IP. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 11.   | Termination                by DOV.                DOV shall have the right, prior to conclusion of the Second Phase                II and                before clinical results are known, to terminate this Amendment upon                30                days’ written notice provided pursuant to Section 12.4 of the Agreement                in                which case (a) all references in the Agreement to DOV 21,947 including                in                Section 1.15 shall be deleted and the compound selected by Merck                pursuant                to Paragraph 10 shall be substituted therefor and (b) Section 9.4                of the                Agreement shall apply to DOV 21,947 as if the Agreement were terminated                by                Merck pursuant to Section 9.2 of the Agreement; provided that such                termination shall not affect the parties’ rights and obligations under                Paragraph 10 of this Amendment. In the event of such a termination                by DOV,                DOV will provide to Merck copies of all DOV’s Information relating to DOV                21,947 that has not previously been provided to Merck. Merck will                have the                right, no later than sixty (60) days after DOV has provided such                Information to Merck, upon written notice and payment of the Reimbursement                Payment, to re-assume all development and other rights and obligations                under the Agreement with respect to DOV 21,947; provided,                however,                that, in the event that Merck’s election to make a Reimbursement Payment                relates to a termination by DOV prior to the commencement of the                Second                Phase II, the component of the Reimbursement Payment payable pursuant                to                this sentence that is attributable to the First Phase II shall be                [***]%                of DOV’s actual costs for the First Phase II ( rather than [***]% of DOV’s                actual costs for the First Phase II). |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.   | Termination                by Merck.                During the term of this Amendment, in addition to the rights Merck                has                pursuant to Sections 9.2 and 9.3 of the Agreement, Merck shall have                the                right to terminate the Agreement upon 30 days’ written notice (i) within                sixty (60) days of DOV presenting to Merck the DOV Plan, or (ii)                if the                Parties do not agree in writing on the design of the Second Phase                II or                what constitutes Successful completion of the Second Phase II. Termination                pursuant to this Paragraph 12 of the Amendment shall be deemed a                termination by Merck pursuant to Section 9.2 of the Agreement. Merck                shall                not elect to terminate the Agreement pursuant to Section 9.2 prior                to the                date that is ninety (90) days following the Amendment Effective                Date. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.   | Reversion                of Rights to Merck.                If Merck makes the payments required by Paragraphs 7 and 9 above,                the                License Exceptions shall terminate, and DOV shall promptly transfer                to                Merck under the Agreement all Information and Inventions created                or                developed by DOV during the term of this Amendment relating to DOV                21,947                and any Information and Inventions created or developed during the                period                shall be governed by the Agreement and the IND for DOV 21,947. Thereupon                the parties shall have all rights and obligations set forth in the                Agreement except as expressly amended by this Amendment. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.   | Joint                Development Committee.                Notwithstanding the provisions of Section 2.3 of the Agreement, during                the                term of this Amendment, and until the reversion of rights to Merck                pursuant to Paragraph 13 of this Amendment, JDC meetings shall be                chaired                by DOV, and Merck shall have the right to waive its participation                in JDC                meetings. DOV shall inform Merck during the JDC meetings of all                correspondence sent to and received from the FDA regarding the                Phase                Ib, First Phase II, and Second Phase II and with respect to the Further                R&D. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 15.   | DOV                216,303 Public Communications.                DOV shall be entitled to publish the results of the DOV 216,303 study                entitled “A Multi-Centered, Double-blind Safety, Efficacy and Tolerability                Study Comparing DOV 216,303 BID 50 mg to Citalopram HBr 20 mg BID                for Two                Weeks in Hospitalized and Outpatient Patients with Major Depressive                Disorder” [***]. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.   | Construction.                The parties intend that this Amendment supersede any inconsistent                terms of                the Agreement or, if not directly inconsistent, be construed so as                to                harmonize the two documents to the extent that the intent of this                Amendment is carried out. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.   | Further                Assurances.                Each party agrees to execute such further papers, agreements, documents,                instruments and the like as may be necessary or desirable to effect                the                purpose of this Amendment and to carry out its                provisions. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.   | Counterparts.                This Amendment may be executed in two or more counterparts, each                of which                will be deemed an original, but all of which will constitute one                and the                same instrument. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*[The      remainder of this page has been left blank intentionally.]*

----

| Name: | Caroline                Dorsa |
|-------|-------------------------------|

| Title: | Treasurer** ** |
|--------|---------------------|

| Name: | Dr.                Leslie Hudson |
|-------|----------------------------------|

| Title: | President                and Chief Executive |
|--------|----------------------------------------------|

----